(EHAB) Enhabit - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022

Stock: Home Health, Hospice, Therapy, Chronic Care

Total Rating 46

Risk 72

Buy Signal 0.65

Medical Care Facilities +15.7
Health Care Services +5.3

Market Cap: 690m
Avg Trading Vol: 14.7M USD

ATR: 2.68%
Peers RS (IBD): 87.10

Risk 5d forecast
Volatility	50.6%
Relative Tail Risk	-18.5%

Reward TTM
Sharpe Ratio	1.11
Alpha	51.80

Character TTM
Beta	0.561
Beta Downside	1.554

Drawdowns 3y
Max DD	54.82%
CAGR/Max DD	-0.01

EPS (Earnings per Share)

EPS CAGR: -68.08%
EPS Trend: -66.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -1.23%
Rev. Trend: -67.5%

Last SUE: -0.84
Qual. Beats: 0

Description: EHAB Enhabit March 03, 2026

Enhabit, Inc. (NYSE: EHAB) operates a nationwide network of home-health and hospice providers, delivering services such as skilled nursing, wound care, infusion therapy, and rehabilitative therapies, as well as comprehensive end-of-life support that includes pain management, counseling, and spiritual care.

In its latest quarter (Q4 2023), Enhabit reported revenue of $162 million, a 7% year-over-year increase driven by a 5% rise in patient admissions and higher case-mix intensity; adjusted EBITDA margin expanded to 6.2%, up from 5.5% in the prior year. The company’s home-health census grew to 8,300 active patients, reflecting robust demand for chronic-disease management.

Key sector catalysts include the aging U.S. population-U.S. Census data projects that adults 65+ will comprise 21% of the population by 2030-and ongoing Medicare policy shifts that favor home-based care over inpatient settings, boosting reimbursement rates for qualified home-health services.

For a deeper dive, you might explore ValueRay’s detailed analysis of EHAB.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income: -11.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.68 > 1.0
NWC/Revenue: 7.46% < 20% (prev 6.30%; Δ 1.17% < -1%)
CFO/TA 0.05 > 3% & CFO 62.2m > Net Income -11.9m
Net Debt (459.6m) to EBITDA (59.2m): 7.76 < 3
Current Ratio: 1.58 > 1.5 & < 3
Outstanding Shares: last quarter (51.1m) vs 12m ago 1.79% < -2%
Gross Margin: 48.43% > 18% (prev 0.47%; Δ 4797 % > 0.5%)
Asset Turnover: 82.75% > 50% (prev 79.52%; Δ 3.22% > 0%)
Interest Coverage Ratio: 0.93 > 6 (EBITDA TTM 59.2m / Interest Expense TTM 36.5m)

Altman Z'' 1.17

A: 0.06 (Total Current Assets 213.7m - Total Current Liabilities 135.5m) / Total Assets 1.23b
B: 0.11 (Retained Earnings 132.4m / Total Assets 1.23b)
C: 0.03 (EBIT TTM 33.8m / Avg Total Assets 1.27b)
D: 0.21 (Book Value of Equity 132.9m / Total Liabilities 631.0m)
Altman-Z'' Score: 1.17 = BB

Beneish M -3.15

DSRI: 0.98 (Receivables 148.7m/150.9m, Revenue 1.05b/1.04b)
GMI: 0.96 (GM 48.43% / 46.56%)
AQI: 0.98 (AQ_t 0.77 / AQ_t-1 0.78)
SGI: 1.01 (Revenue 1.05b / 1.04b)
TATA: -0.06 (NI -11.9m - CFO 62.2m) / TA 1.23b)
Beneish M-Score: -3.15 (Cap -4..+1) = AA

What is the price of EHAB shares?

As of March 04, 2026, the stock is trading at USD 13.60 with a total of 2,030,300 shares traded.
Over the past week, the price has changed by +0.29%, over one month by +25.69%, over three months by +45.61% and over the past year by +61.33%.

Is EHAB a buy, sell or hold?

Enhabit has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold EHAB.

StrongBuy: 1
Buy: 0
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the EHAB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	13.4	-1.2%
Analysts Target Price	13.4	-1.2%

EHAB Fundamental Data Overview March 03, 2026

P/E Forward = 24.6914
P/S = 0.6584
P/B = 1.2152
Revenue TTM = 1.05b USD
EBIT TTM = 33.8m USD
EBITDA TTM = 59.2m USD
Long Term Debt = 441.5m USD (from longTermDebt, last quarter)
Short Term Debt = 35.2m USD (from shortTermDebt, last quarter)
Debt = 516.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 459.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (689.9m + Debt 516.5m - CCE 56.9m)
Interest Coverage Ratio = 0.93 (Ebit TTM 33.8m / Interest Expense TTM 36.5m)
EV/FCF = 19.89x (Enterprise Value 1.15b / FCF TTM 57.8m)
FCF Yield = 5.03% (FCF TTM 57.8m / Enterprise Value 1.15b)
FCF Margin = 5.52% (FCF TTM 57.8m / Revenue TTM 1.05b)
Net Margin = -1.14% (Net Income TTM -11.9m / Revenue TTM 1.05b)
Gross Margin = 48.43% ((Revenue TTM 1.05b - Cost of Revenue TTM 540.3m) / Revenue TTM)
Gross Margin QoQ = 48.48% (prev 46.94%)
Tobins Q-Ratio = 0.94 (Enterprise Value 1.15b / Total Assets 1.23b)
Interest Expense / Debt = 1.61% (Interest Expense 8.30m / Debt 516.5m)
Taxrate = 21.62% (3.20m / 14.8m)
NOPAT = 26.5m (EBIT 33.8m * (1 - 21.62%))
Current Ratio = 1.58 (Total Current Assets 213.7m / Total Current Liabilities 135.5m)
Debt / Equity = 0.91 (Debt 516.5m / totalStockholderEquity, last quarter 566.8m)
Debt / EBITDA = 7.76 (Net Debt 459.6m / EBITDA 59.2m)
Debt / FCF = 7.95 (Net Debt 459.6m / FCF TTM 57.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.94% (Net Income -11.9m / Total Assets 1.23b)
RoE = -2.18% (Net Income TTM -11.9m / Total Stockholder Equity 546.5m)
RoCE = 3.42% (EBIT 33.8m / Capital Employed (Equity 546.5m + L.T.Debt 441.5m))
RoIC = 2.56% (NOPAT 26.5m / Invested Capital 1.03b)
WACC = 5.10% (E(689.9m)/V(1.21b) * Re(7.98%) + D(516.5m)/V(1.21b) * Rd(1.61%) * (1-Tc(0.22)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.09%
[DCF] Terminal Value 85.93% ; FCFF base≈55.7m ; Y1≈53.5m ; Y5≈52.4m
[DCF] Fair Price = 21.93 (EV 1.57b - Net Debt 459.6m = Equity 1.11b / Shares 50.6m; r=5.90% [WACC]; 5y FCF grow -5.17% → 2.90% )
EPS Correlation: -66.09 | EPS CAGR: -68.08% | SUE: -4.0 | # QB: 0
Revenue Correlation: -67.53 | Revenue CAGR: -1.23% | SUE: -0.84 | # QB: 0
EPS next Year (2026-12-31): EPS=0.60 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+3 | Growth EPS=+7.4% | Growth Revenue=+4.6%

Additional Sources for EHAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle